Website Updates Website Updates Research Grants and Email Patient Info Leaflets 31 March 2022 The research grants page has been updated and a list of previous grants can now be viewed. Patient information pages now have a link so that the page link can be shared with patients via email. Read more
BOFAS Surveys Results BOFAS Surveys Results Now Live 24 March 2022 The results of BOFAS surveys to the membership which have been published / presented can now be viewed here. Read more
BOFAS 2022 Recap BOFAS 2022 Recap BOFAS 2022 is over, but you can catch up here! 19 March 2022 Read more
20Apr2026 BOFAS Diabetic Foot Principles Course 20/04/2026 Read more BOFAS Diabetic Foot Principles Course 20th April 2026, Delta by Marriott Hotel, Milton Keynes £150.00 Read more
29Apr2026 BOFAS Trauma Course 29/04/2026 Read more BOFAS Trauma Course 29th April 2026, Bristol £150 Read more
15May2026 BOFAS Allied Health Professionals Course 15/05/2026 Read more BOFAS Allied Health Professionals Course 15th May 2026, Bournemouth Read more
2Jul2026 BOFAS Basics & Advanced Arthroscopy Skills Course 02/07/2026 Read more BOFAS Basics & Advanced Arthroscopy Skills Course 2nd-3rd July 2026, Solihull Read more
1Oct2026 BOFAS Principles Course 01/10/2026 Read more BOFAS Principles Course 1st-2nd October 2026, Glasgow £325.00 Read more
6May2026 Nordic Foot & Ankle Congress 06/05/2026 - 07/05/2026 Read more Nordic Foot & Ankle Congress BOFAS Members have been invited to the Nordic Foot & Ankle Congress May 6/7 2026 in Oslo. Read more
Karan Malhotra / 14 February 2021 / Categories: Abstracts, 2021, Poster DVT and Achilles tendon rupture - a better pill to swallow? G. Scott, A. Biggs, A. Carne, M. Rogers, M. Solan Background: The BOFAS Guidance regards Achilles rupture patients as particularly high risk for VTE. Many hospitals use 6-weeks of low molecular weight heparin (LMWH) injections which are unpleasant for patients and result in reduced compliance. An extended course of prophylaxis is advised following hip and knee arthroplasty, however Novel Oral Anti-Coagulant (NOAC) tablets are licensed. We offered Rivaroxaban to our Achilles patients as an alternative. Since this is “off-license”, we developed an information sheet and consent form. In this study we compared VTE prophylaxis outcomes in our Achilles rupture patients. Methods: We retrospectively reviewed patients diagnosed during three different periods between 2010 and 2019. During the first patients were treated in any fracture clinic. Chemical prophylaxis was not always prescribed. In the second period patients were triaged to a Foot & Ankle clinic. VTE prophylaxis was universal but not standardised. The third period saw patients managed by one F&A surgeon using the Rivaroxaban protocol. Thromboembolic event or significant bleeding within 3 months of treatment were recorded outcomes. Results: Two hundred and thirty patients with Achilles tendon rupture were identified. Thirty-one were excluded because they took anticoagulants already or had a DVT on initial USS. There were no secondary bleeding episodes or fatal PEs. Forty patients had no prophylaxis and 7.5% of these developed a symptomatic DVT or PE. Of the 80 patients managed with LMWH, 6.25% suffered a thromboembolic event. A total of 79 patients were given Rivaroxaban and zero suffered a DVT or PE. Conclusion: Numbers here are small, but suggests Rivaroxaban is an appropriate alternative to LMWH. Poor compliance due to pain and bruising from injections isn't relevant with a tablet that also doesn't require any patient/family education. Rivaroxaban has led to improved VTE rates for patients with Achilles tendon rupture in our hospital with no complications. Print 7407 Tags: AchillesVTE Documents to download P1 G Scott BOFAS Poster Submission(.pdf, 140.93 KB) - 1963 download(s)